||COM STK USD0.01 (DI/REG S)
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Maxcyte (DI/S) Share Discussion Threads
Showing 1 to 19 of 25 messages
Chat Pages: 1
|>>davep4, indeed. I wish I had as much in this one as have in Cyan. I seem to have an exceptional talent for underinvesting in shares which take off like this one!|
|timbo003 let's hope Cyan does the same soon!|
|This week's (unexpected) performance has to be worth an animated gif!
As much as I would have liked to have attended the AGM yesterday, I think travelling over to the Maryland in the US would have been beyond the call of duty given the size of my modest holding|
I hope they do better than the most recent "Best Technology" award winners, for example:
* 2015 award winner: Advanced Oncotherapy (down > 45% in 12 months)
* 2014 award winner: Rex Bionics (down > 85% in 24 months)
* 2013 award winner: Wandisco (down > 85% in 36 months).
|Hey guys, you have just won the Aim Technology Company of the Year award for 2016, don't all cheer at once :)|
I see there's an updated research note here:
|Morning, short TV interview for Maxcyte's results announced this morning
|Finals out today, they look okay to me, but I am not that well up on the business (yet)
There is an analyst telecom today with slides available on the web site later (see below)
This evening they are presenting at the Shares Magazine Investor Seminar (near Tower Hill tube) along with 3 others, so I will go along to that one, it starts at around 18.00 (see details in last post)
Conference call for analysts
A briefing for analysts will be held at 11.00am BST on 27 September 2016 at the offices of Panmure Gordon & Co., One New Change, London, EC4M 9AF. There will be a simultaneous live conference call with Q&A and the presentation will be available on MaxCyte's website at http://www.maxcyte.com/
Participant dial-in: 08006940257
International dial-in: +44 (0) 1452 555566
Participant code: 86595211
An audio replay file will be made available shortly afterwards via the Company website:
|Maxcyte will be presenting at the Shares Mag investor evening on September 27th
I've already booked my place.|
|There's a new interview with MaxCyte CEO, Doug Doerfler on Directors talk
He will be visiting London in September. so hopefully that will include an investor road show (I have a growing list of questions I want to ask).|
|MaxCyte Inc (LON:MXCT) Chief executive Doug Doerfler very confident over prospects for the current year.
13th July 2016
|Encouraging trading statement this morning.
Also a new research note out with a target price of 184p/share
|MaxCyte Right here, right now: catching the CAR-T wave
12th July 2016
MaxCyte is already delivering strong revenue growth, due to demand for its flow electroporation devices in drug discovery and cell therapy.|
MaxCyte Right here, right now: catching the CAR-T wave
12th July 2016
MaxCyte is already delivering strong revenue growth, due to demand for its flow electroporation devices in drug discovery and cell therapy.
MaxCyte Scalable High Throughput Transfection
|There's a new video interview on ProactiveInvestors with Doug Doerfler (MaxCyte CEO) which is well worth a look, he seems very excited about their CARMA technology platform, the first product (to showcase the technology) is effective in Mouse and should be ready for the clinic (platinum resistant ovarian cancer) in H2/2017
|There's a useful article over on Proactiveinvestors (dated May 2nd) which explains why Maxcyte (a US based company) went for an AIM IPO rather than a Nasdaq IPO.
|Thanks oshy, that was very helpful.|
Short TV clip on MaxCyte:
|That was a good start to life on Aim, up circa 10% with only three trades (total 2,407 shares traded).
All a bit academic for me, as this needs to be a three year hold for the tax breaks.|
Chat Pages: 1